Oncology Frontier: The QUASAR 2 trial compared standard chemotherapy versus capecitabine and bevacizumab in colorectal cancer. What are the main results available from this trial?

 

　　《肿瘤瞭望》：QUASR 2研究比较了标准化疗与卡培他滨联合贝伐单抗治疗结直肠癌的疗效，这项研究的主要结果是什么？

 

　　Dr Kerr: I work at the University of Oxford which has a very large cancer trials office. In fact， we have been running the UK’s adjuvant trials portfolio for the past twenty years. One of the most recent studies， QUASAR 2， compared a single agent capecitabine versus a combination of capecitabine with bevacizumab， the antiangiogenic drug. We have recruited over 2000 patients to the trial. The results are in but they are embargoed until the ESMO meeting in Madrid where there will be a presentation. So everyone will have to come to the European Society of Medical Oncology meeting in Madrid. It is going to be a great meeting and the results will be available there. We have reported on toxicity data from the trial though. Capecitabine does cause a variety of side effects such as hand-foot syndrome and diarrhea， but we have noted that the addition of bevacizumab does cause an excess of hypertension.

 

　　Kerr教授:我工作的牛津大学拥有一个庞大的肿瘤临床试验机构。事实上，在过去的二十年中，我们一直运行英国的辅助试验组合。最近的一项研究，QUASAR 2，比较单独应用卡培他滨与卡培他滨联合贝伐单抗（抗血管生成药）的效果。我们为该试验募集到2000多名患者。试验结果已出，但是在马德里举行的ESMO会议上作出介绍之前，还不能公开。因此我们不得不去参加马德里举行的欧洲肿瘤内科学会会议。这是一场盛大的会议，届时结果将会公开。但是目前我们已经报道了该临床试验的毒理学数据。卡培他滨确实能引起许多不良反应例如手足综合征和腹泻等，但是我们也已经发现贝伐单抗加入治疗的确会引起过量的高血压发生。